Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information
By Denny Jacob
Boston Scientific and Axonics each received a request for additional information from the Federal Trade Commission regarding a previously agreed upon merger.
The medical device manufacturer in January agreed to acquire Axonics for about $3.7 billion in cash, resulting in Axonics becoming a wholly-owned subsidiary of Boston Scientific.
The additional request for information extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after both sides have substantially complied with the request, Boston Scientific said in a securities filing.
The merger is now expected to be completed in the second half of 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 04, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software